FDA Approved First Treatment for Symptomatic Dermographism

Regulators cleared Novartis drug Rhapsido to address a condition that affects thousands of chronic hives patients.

Updated on Oct. 7, 2026 in Allergies

Isometric editorial illustration of a sterile medical vial and dropper, representing regulatory health approval and clinical treatment. — The FDA approved Novartis' Rhapsido for treating symptomatic dermographism and chronic spontaneous urticaria in adults who do not respond to antihistamines. AI Illustration. Upload story photo >

Live Poll

Do you believe new pharmaceutical treatments for chronic skin conditions will improve your overall quality of life?

The FDA approved Rhapsido as the first prescription treatment specifically for adults with symptomatic dermographism. The medication is also approved for chronic spontaneous urticaria, targeting patients who do not find relief through standard H1 antihistamines.

Why it matters

This approval provides a new clinical option for patients suffering from persistent hives when existing treatments fail. Symptomatic dermographism and chronic spontaneous urticaria together represent the vast majority of chronic hives cases in adults.

In the Phase 3 RemIND trial, 29.3% of patients treated with Rhapsido achieved complete hive clearance by the 12-week mark, compared to 14.0% in the placebo group. This patient population comprises those failing to achieve control with H1 antihistamines.

The players

FDA

The Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices in the United States.

Novartis

Novartis is a multinational pharmaceutical corporation headquartered in Switzerland that develops and manufactures a wide range of medical treatments.

The details

Rhapsido targets patients whose symptoms persist despite using H1 antihistamines, filling a gap for those with severe skin sensitivity. Novartis confirmed that the drug maintained a consistent safety profile throughout clinical trials lasting up to 24 weeks.

Wednesday: The FDA granted approval for Rhapsido.
Week two: Some patients began reporting clinical results during the study.
12-week mark: Patients achieved complete response from hives in the trial.
Up to 24 weeks: Clinical trials demonstrated a consistent safety profile for the medication.

Health Landscape

The approval of Rhapsido expands the range of targeted treatments for chronic hives beyond traditional antihistamines. This milestone follows the established path of the FDA's drug approval process for chronic spontaneous urticaria to address unmet needs in dermatological care.

Patients who have struggled to manage symptomatic dermographism with standard H1 antihistamines may now have access to a targeted prescription option. Individuals should consult with their healthcare provider to determine if they meet the clinical criteria for this new treatment.

The takeaway

The addition of Rhapsido to the treatment landscape marks a significant shift for adults who fail to find relief through existing antihistamine therapies. Patients are encouraged to track their symptoms consistently to better discuss potential therapeutic changes with their doctors.